Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

Role of myeloid-derived suppressor cells in tumor recurrence

Biomedicines, Free Full-Text

Wnt/β-catenin signaling in cancers and targeted therapies

Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update - Cytotherapy

Genes, Free Full-Text

Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer

Current and Evolving Therapies for Metastatic Pancreatic Cancer: Are We Stuck With Cytotoxic Chemotherapy?

WO2016087994A1 - Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment - Google Patents

Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future - The Lancet Oncology

Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy, Biomarker Research

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors

Frontiers Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: Tumour microenvironment components

Targeting Myeloid-Derived Suppressor Cells for Premetastatic Niche Disruption After Tumor Resection

Biomedicines, Free Full-Text